Rna Diagnostics Inc.

Rna Diagnostics solves a high priority problem in cancer treatment with the first real time chemotherapy guidance tool.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded March 2010
  • Employees 10
  • Website http://rnadiagnostics.com

Company Summary

Rna Diagnostics has developed real-time cancer chemotherapy guidance tools. The RNA Disruption Assay (RDA™) is the only diagnostic tool that predicts early in treatment how a patient will respond to chemotherapy. Reduction of unnecessary chemotherapy is a top priority for breast oncologists. RDA™ improves patient outcomes while lowering breast cancer treatment cost.

Team

  • Amadeo, PhD Parissenti
    CSO

    Professor of biochemistry at Laurentian University. Over 20 years experience studying tumour resistance to chemotherapy.

  • John Jordan, MBA, CMA, CPA/ABV (US)
    CFO

    Financial executive with 15 years experience taking early stage technology companies from start-up through to successful exit

  • Kenneth, MD, FRPCP Pritzker
    CEO

    Former Chief, Pathology & Lab Medicine at Mount Sinai Hospital, Toronto. Internationally recognized leader in molecular diagnostics

  • John Connolly, MBA
    VP Corporate Development

    20 year entrepreneur in medical technology business development , former patrner at MDS Capital Corp, Health Science venture capital investor

  • John Connolly

Advisors

  • Stikeman Elliott
    Lawyer
    Unconfirmed

Previous Investors

  • Niagara Angels, Ontario Centres of Excellence
    Unconfirmed
  • York Angel Investors
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free